UCL Discovery
UCL home » Library Services » Electronic resources » UCL Discovery

Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease

Howe, R; Mirakian, RM; Pillai, P; Gane, S; Darby, YC; Scadding, GK; (2014) Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease. World Allergy Organization Journal , 7 (1) , Article 18. 10.1186/1939-4551-7-18. Green open access

[thumbnail of 1939-4551-7-18.pdf]
Preview
Text
1939-4551-7-18.pdf

Download (860kB) | Preview

Abstract

Background Aspirin – exacerbated respiratory disease can prove difficult to control. Oral aspirin desensitization is effective, but has adverse effects and may not be cardio-protective at the high doses needed. Objective To examine the effectiveness of aspirin administered in lower doses via the nose. Methods An audit of 121 patients with aspirin exacerbated respiratory disease (AERD), 105 of whom were treated with intranasal lysine aspirin in gradually increasing doses following positive lysine aspirin challenge. Results Treatment was associated with subjective symptomatic improvement or stabilization in 60 of 78 patients at 3 months and 19 of 27 at 12 months. Nasal inspiratory peak flow, olfaction, exhaled and nasal nitric oxide levels were significantly improved (p < 0.05 for all). Patients with positive skin prick tests and those with later onset (>40 years) AERD improved more than non-atopics and those with early onset AERD. Asthma outcomes over 1 year were assessed by questionnaire in 22 patients on lysine aspirin and in 20 who were positive on challenge but who either refused treatment or took it only briefly (less than or equal to 3 months). There was a significant decrease in emergency visits (p = 0.0182), hospitalization (p = 0.0074) and oral steroid use (p = 0.004) in those on nasal lysine aspirin for a year. Gastrointestinal side effects occurred in 3.8%, lower than those reported for oral aspirin therapy. Conclusions and Clinical Relevance This form of therapy might reduce the need for expensive monoclonal antibodies in AERD patients.

Type: Article
Title: Audit of nasal lysine aspirin therapy in recalcitrant aspirin exacerbated respiratory disease
Open access status: An open access version is available from UCL Discovery
DOI: 10.1186/1939-4551-7-18
Publisher version: http://dx.doi.org/10.1186/1939-4551-7-18
Language: English
Additional information: © 2014 Howe et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Keywords: Aspirin exacerbated respiratory disease; Lysine aspirin; Nasal polyposis; Late onset asthma
UCL classification: UCL
UCL > Provost and Vice Provost Offices
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Infection and Immunity
URI: https://discovery.ucl.ac.uk/id/eprint/1471487
Downloads since deposit
102Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item